16 terminated. 16 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Terminated 16 |
| Phase 1 | 5 | Terminated 5 |
| Phase 3 | 1 | Terminated 1 |
Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer Amcenestrant, Fulvestrant, Anastrozole - Breast Cancer Metastatic | Phase 2 | Terminated | Sanofi | 367 | 2019-10-22 | 2026-02-24 |
| Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer Durvalumab, Anastrozole 1mg, Letrozole 2.5mg - Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 17 | 2019-04-26 | 2022-05-31 |
| Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer Pembrolizumab/ Exemestane/ Leuprolide - Premenopausal Breast Cancer | Phase 1 / Phase 2 | Terminated | National Taiwan University Hospital | 16 | 2017-09-15 | 2023-02-22 |
| GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer GS-5829, Exemestane, Fulvestrant - Advanced Estrogen Receptor Positive HER2- Breast Cancer | Phase 1 / Phase 2 | Terminated | Gilead Sciences | 14 | 2017-01-10 | 2019-08-07 |
| Exemestane-RAD001-Metformin Everolimus, Exemestane, Metformin - Breast Cancer | Phase 2 | Terminated | M.D. Anderson Cancer Center | 23 | 2012-09-01 | 2020-06-19 |
| Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer Dovitinib, Aromatase Inhibitors - Breast Cancer | Phase 1 / Phase 2 | Terminated | Georgetown University | 12 | 2012-04-01 | 2018-02-09 |
| Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer Exemestane, Sutent - Metastatic Breast Cancer | Phase 1 / Phase 2 | Terminated | Baylor Breast Care Center | 4 | 2010-03-01 | 2020-07-24 |
| Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer Bosutinib, exemestane, Exemestane - Advanced Breast Cancer | Phase 2 | Terminated | Pfizer | 42 | 2009-02-01 | 2012-11-05 |
| Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer SOD1 inhibitor ATN-224, exemestane, protein expression analysis - Breast Cancer | Phase 2 | Terminated | Cancer Research UK | 111 | 2008-06-01 | 2013-07-10 |
| Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole) - Breast Cancer | Phase 2 / Phase 3 | Terminated | The Netherlands Cancer Institute | 10 | 2008-04-01 | 2017-09-14 |
| Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer anastrozole, exemestane, letrozole - Breast Cancer | Phase 2 | Terminated | Mayo Clinic | 4 | 2007-12-01 | 2016-02-05 |
| A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer exemestane, sunitinib malate - Breast Neoplasms | Phase 1 / Phase 2 | Terminated | Pfizer | 6 | 2007-06-01 | 2010-09-21 |
| Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer CP-751,871, exemestane, Fulvestrant - Breast Neoplasms | Phase 2 | Terminated | Pfizer | 219 | 2007-02-01 | 2015-10-28 |
| Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer exemestane, triptorelin pamoate, capecitabine - Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Terminated | University of Washington | 28 | 2005-08-01 | 2017-07-11 |
| Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women exemestane - Breast Neoplasms | Phase 2 | Terminated | Pfizer | 100 | 2002-06-01 | 2012-02-16 |
Breast Neoplasms (13) · Neoplasm Metastasis (2) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1)
Pfizer (4) · Baylor Breast Care Center (1) · Cancer Research UK (1) · Georgetown University (1) · Gilead Sciences (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · National Taiwan University Hospital (1) · OHSU Knight Cancer Institute (1) · Sanofi (1) · The Netherlands Cancer Institute (1) · University of Washington (1)
United States (12) · Canada (4) · Belgium (3) · United Kingdom (3) · Argentina (2) · Australia (2) · Brazil (2) · China (2) · Italy (2) · Netherlands (2) · Poland (2) · Spain (2) · Taiwan (2) · Czechia (1) · France (1)
Adrian L. Harris, MD (1) · Charles D Lopez, MD, PhD (1) · Claudine Isaacs, MD (1) · Donald W Northfelt, M.D. (1) · Hannah Linden (1) · Hung Khong, MD (1) · Mothaffar Rimiawi, MD (1) · Sjoerd Rodenhuis, MD (1) · Timothy J Hobday, M.D. (1) · Vicente Valero, MD (1) · Vivek Roy, MD (1)
PMID 24674873, PMID 37348019, PMID 39730000, PMID 41697438
2016 (1), 2018 (1), P30CA015083 (1)